David Kotler

David Kotler

Dechert LLP

Contact  |  View Bio  |  RSS

Latest Publications

Share:

Federal Court Issues Trial Ruling in Section 36(b) “Manager of Managers” Lawsuit: AXA Advisory and Administrative Fees Held Not to...

The U.S. District Court for the District of New Jersey issued its post-trial ruling on August 25, 2016 in Sivolella v. AXA Equitable Life Insurance Company—the first Section 36(b) trial decision since 2009. The Court...more

9/20/2016 - AXA Equitable Life Burden of Proof Fees Fiduciary Duty Gartenberg Factors Insurance Industry Investment Adviser Investment Company Act of 1940 Investment Funds Life Insurance Mutual Funds Section 36(b)

Federal Court Issues Trial Ruling in Section 36(b) "Manager of Managers" Lawsuit

AXA Investor Fees Held Not To Constitute a Breach of Fiduciary Duty - The U.S. District Court for the District of New Jersey issued its trial ruling on August 25, 2016 in Sivolella v. AXA Equitable Life Insurance...more

8/30/2016 - Breach of Duty Burden of Proof Excessive Fees Fiduciary Duty Fund Managers Investment Adviser Investment Company Act of 1940 Mutual Funds Private Right of Action Shareholders

Financial Services Quarterly Report - Third Quarter 2015: Recent Developments in U.S. “Excessive Fee” Litigation

The U.S. mutual fund industry is poised to see significant developments in the ongoing wave of Section 36(b) “excessive fee” litigation. Days apart in August, the Seventh Circuit Court of Appeals affirmed the grant of summary...more

10/7/2015 - Appeals Arms Length Transactions Board Deferance Board of Directors Excessive Fees Fiduciary Duty Financial Adviser Gartenberg Factors Investment Adviser Investment Company Act of 1940 Mutual Funds Private Right of Action SCOTUS Section 36(b) Shareholders Summary Judgment

Dechert Survey of Securities Fraud Class Actions Brought Against U.S. Life Sciences Companies

Publicly Traded Life Sciences Companies in the United States Are an Increasingly Popular Target of Securities Fraud Class Action Lawsuits - The past year was particularly noteworthy with respect to the relative number...more

3/19/2015 - Biotechnology Class Action Compliance Disclosure Requirements Insider Trading Life Sciences Medical Devices Misrepresentation Pharmaceutical Industry Popular Publicly-Traded Companies Rule 10b-5 Securities Fraud Surveys

U.S. Fund Litigation Update: Where We are Now and Where We Could be Headed

Five years removed from the credit crisis and “great recession” of 2008, the U.S. fund industry still faces substantial litigation risk, both in terms of ongoing cases that challenge the core of the advisory/sub-advisory...more

3/28/2014 - Investment Companies Investment Company Act of 1940 Investment Funds SEC Securities Act of 1933 Securities Exchange Act

Dechert Survey of Securities Fraud Class Actions Brought Against U.S. Life Sciences Companies

Publicly Traded Life Sciences Companies in the United States Remain an Increasingly Popular Target of Securities Fraud Class Action Lawsuits: The past year was particularly noteworthy with respect to the absolute and...more

3/20/2013 - Amgen Inc. v Connecticut Retirement Plans Class Action FDA Fraud Life Sciences Marketing Off-Label Promotion Pharmaceutical Industry Securities Fraud

6 Results
|
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×